10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Handelsinvest Investeringsforvaltning

Handelsinvest Investeringsforvaltning decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 34.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,993 shares of the company’s stock after selling 2,073 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in 10x Genomics were worth $150,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its position in 10x Genomics by 113.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after purchasing an additional 371 shares during the last quarter. Mirador Capital Partners LP raised its position in 10x Genomics by 3.4% in the 1st quarter. Mirador Capital Partners LP now owns 28,825 shares of the company’s stock valued at $1,082,000 after purchasing an additional 940 shares during the last quarter. Vanguard Group Inc. raised its position in 10x Genomics by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 9,011,332 shares of the company’s stock valued at $504,274,000 after purchasing an additional 107,815 shares during the last quarter. Goldman Sachs Group Inc. raised its position in 10x Genomics by 0.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 372,873 shares of the company’s stock valued at $20,866,000 after purchasing an additional 1,815 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its position in 10x Genomics by 0.7% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 502,471 shares of the company’s stock valued at $28,118,000 after purchasing an additional 3,350 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on TXG shares. Guggenheim reiterated a “neutral” rating on shares of 10x Genomics in a research report on Tuesday, June 25th. Barclays reduced their target price on shares of 10x Genomics from $36.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 29th. TD Cowen cut shares of 10x Genomics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $57.00 to $32.00 in a research note on Wednesday, May 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $45.00.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 4,877 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the transaction, the chief executive officer now directly owns 889,641 shares in the company, valued at approximately $21,618,276.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Serge Saxonov sold 4,877 shares of 10x Genomics stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the sale, the chief executive officer now directly owns 889,641 shares in the company, valued at $21,618,276.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Justin J. Mcanear sold 2,936 shares of 10x Genomics stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $71,344.80. Following the sale, the chief financial officer now owns 146,203 shares of the company’s stock, valued at $3,552,732.90. The disclosure for this sale can be found here. In the last three months, insiders sold 11,900 shares of company stock worth $289,170. 10.03% of the stock is owned by corporate insiders.

10x Genomics Stock Performance

NASDAQ:TXG opened at $18.75 on Thursday. The firm has a 50-day moving average price of $23.08 and a two-hundred day moving average price of $36.22. 10x Genomics, Inc. has a twelve month low of $18.39 and a twelve month high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm had revenue of $141.01 million during the quarter, compared to the consensus estimate of $142.24 million. During the same period last year, the firm posted ($0.44) EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.53 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.